哈藥股份(600664.SH):中藥二廠已收到全部徵收補償款7285.13萬元
格隆匯3月17日丨哈藥股份(600664.SH)公佈,經公司2021年10月18日第九屆董事會第十五次會議審議批准,中藥二廠與哈爾濱市道外區人民政府房屋徵收辦公室簽署了《房屋徵收補償協議》。根據協議約定,中藥二廠將獲得補償款合計7285.13萬元。公司已於2021年10月30日公吿中藥二廠收到第一筆補償款4000萬元。
近日,中藥二廠收到第二筆徵收補償款328.51萬元,截止公吿日,已收到全部徵收補償款人民幣7285.13萬元。至此,中藥二廠與房屋徵收方簽署的《房屋徵收補償協議》已全部履行完畢。
此次收到的補償款,根據《企業會計準則》等相關規定,在扣除相關税費後,預計將增加公司當期損益約為5323萬元,具體會計處理及金額以年審會計師年度審計確認後的結果為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.